R ANTIPSORIATIC ACTIVITY OF HYDROGEL CONTAINING NANOSTRUCTURED LIPID CARRIER (NLC) ENTRAPPED WITH TRIAMCINOLONE ACETONIDE
Antipsoriatic Activity of Hydrogel
Keywords:Nanostructured lipid Carrier; Hydrogel; Antipsoriatic activity; Irritation study; Triamcinolone acetonide
Objective: The aim of present study was to prepare triamcinolone acetonide (TA) loaded NLCs hydrogel for antipsoriatic activity.
Methods: A Nanostructured lipid carrier (NLCs) was prepared by using solvent diffusion and high pressure homogenization methods. NLCs dispersion was characterized by particle size, zeta potential, scanning electron microscopy (SEM), differential scanning calorimetry, and an in vitro release study. Optimized NLC incorporated into the hydrogel and characterized for rheological properties, drug content, in-vitro drug release, stability study, skin irritation and antipsoriatic activity for optimized batch of hydrogel.
Results: Optimized NLCs loaded with TA were exhibited spherical shape with particle size 286±0.07nm, polydispersity index 0.317, zeta potential -21.91±0.05mV and entrapment efficiency 86.19±0.06% respectively. The drug release of optimized batch was 8.34 % and 88.84±0.08% at 1h & 8h respectively. The release kinetics of the optimized NLCs best fitted the peppas-korsmeyer model. The results of NLC hydrogel formulations were spreadability 27.4±0.06-11.76±0.07 g.cm2/sec, drug content 65.60±0.05%-74.50±0.02%, in vitro drug release 87.52±0.04%, primary irritation index was 0.0752, it indicates barely perceptible irritation. Histopathological studies showed that, in psoriasis-induced animal treated with TA loaded NLC hydrogel, marked reduction in thickness of epidermis, as compared to conventional gel formulation. It shows the increase % orthokeratosis 88.69% and % drug activity 54.23% than the marketed formulation.
Conclusion: The present results demonstrated that hydrogel based NLC shows the better and effective drug delivery for the management of psoriasis.
Salunkhe SS, Bhatia NM, Bhatia MS. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain. Drug Deliv. 2016;23:1306-16.
Carmona Ribeiro AM. Biomimetic nanoparticles: Preparation, characterization and biomedical applications. Int J Nanomed. 2010;5:249-59.
Kovacs SZ, Berko E, Csany I. Development of nanostructured lipid carriers containing salicylic acid for dermal use based on the Quality by Design method. Eur J Pharm Sci. 2016:4-5.
Muller RH et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv. 2002;54:131-55.
Pardeike J, et al. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366:170-84.
Patwekar SL, Pedewad SR. Development and evaluation of nanostructured lipid carriers based gel of Isotretinoin. J Particul Sci Technol.2017:286-90
Muller RH, Ruh D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. J Pharm Res Int. 1997;14:458-62.
Panda R, Kuotsu K. Fabrication, characterization, and in vitro evaluation of Pegylated glyceride labrasol nanostructured lipid carrier composite of methotrexate: the pathway to effective cancer therapy. Asian J Pharm Clin Res. 2019;12:29-37.
Pradhan M, Singh D, Singh MR. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J Control Release 2013;170:380-95.
Coope H, Mckenna DJ, Alexandroff AB. Long term safety of biologics in the treatment of psoriasis. Psoriasis: targets and therapy. 2013:1-9.
Knudsen NO, Jorgensen L, Hansen J, Vermehren C, Frokjaer S. Targeting of liposome associated calcipotriol to the skin: effect of liposomal membrane fluidity and skin barrier integrity. Int J Pharm. 2011;416:478-85.
Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014;70:146-67.
Reich K. The concept of psoriasis as a systemic inflammation: Implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(2):3-11.
Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta. 2004;1663:61-73.
Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology. Am J Clin Dermatol.2002;3:47-58.
Dixit CM, Akhil S, Mukundan S, Gupta S. Development and in vitro evaluation of nanolipid carrier of Clobetasol Propionate and Promaxine Hydrochloride for topical delivery. Int J App Pharm. 2018;10:28-36.
Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Indian J Dermatol Venereol Leprol. 2010;76:612-21.
Zhang YT, Shen LN, Wu Z H, Zhao JH, Feng NP. Evaluation of skin viability effect on ethosome and liposome mediated psoralen delivery via cell uptake. J Pharm Sci. 2104;103(3):120-26.
Hu FQ, Jiang SP, Du YZ. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf Biointerfaces. 2005;45:167-73.
Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo‐controlled, double‐blind study. Trop Med Int Health.1996;1:505-9.
Potdar D, Hirwani RR, Dhulap S. Phyto-chemical and pharmacological applications of Berberis aristata. Fitoterapia. 2012;83:817-30.
More B, Sakharwade S, Tembhurne S, Sakarkar D. Evaluation for skin irritancy testing of developed formulations containing extract of Butea monosperma for its topical application. Int J Toxicol Appl Pharmacol.2013;3(1):10-13.
Zhang JQ, Liu J, Li XL, Jasti BR. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv. 2007;14:381-87.
Zou DN, Zhang DR, Zhou XH. (2008). HPLC determination of entrapment efficiency of matrine-loaded albumin nanoparticles. Chin J Pharm Ana.2008; 28:93-6.
Sonawane R, Harde H, Katariya M, Agrawal S, Jain S. Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert Opin. Drug Deliv.2014;11(12):1833-47.
Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377-90.
Lin YK, Yang SH, Chen CC, Kao HC, Fang JY. Using imiquimod-induced psoriasis-like skin as a model to measure the skin penetration of anti-psoriatic drugs. PLoS One. 2015;10(9):e0137890.
Qin ZM, Chen F, Chen DM, Wang T. Transdermal permeability of triamcinolone acetonide lipid nanoparticles. Int J Nanomedicine. 2019:14 2485-95.
Md. Sarfaraz A, Md. Sajid A, Nawazish A, Md Intakhab A. Design and Characterization of Nanostructure Topical Gel of Betamethasone Dipropionate for Psoriasis. J. Appl. Pharm. Sci.2012: 2(10):148-58. DOI: 10.7324/JAPS.2012.21029
Vjayalakshmi A, Ravichandiran V, Malarkodi V, Nirmala S, Jayakumari S. Screening of flavonoid “quercetin” from the rhizome of Smilax china Linn. For anti-psoriatic activity. Asian Pac J Trop Biomed. 2012;2:269-75.
Skuric J, Orolic N, Kolaric D, Dikic D, Benkovic V. AH. Effectivity of flavonoids on animal model psoriasis-thermographic evaluation. Period Biol. 2011;57:457-63
How to Cite
Copyright (c) 2022 Anilkumar Jalindar Shinde
This work is licensed under a Creative Commons Attribution 4.0 International License.